Table 4 Characteristics of patients with and without SAMS among Atorvastatin users (N = 352)
Factor | SAMS (N = 96) | No SAMS (N = 256) | O.R (95% CI) | P-value |
|---|---|---|---|---|
Gender | ||||
Male (N = 264) | 64(24.24%) | 200 (75.76%) | 1.7857 (1.0642 to 2.996) | 0.0281 |
Female (N = 88) | 32 (36.36%) | 56 (63.64%) | ||
Age | ||||
21–55 (N = 175) | 45 (25.7%) | 130 (74.3%) | 1.1693(0.7310 to 1.8706) | 0.5141 |
56–82 (N = 177) | 51 (28.8%) | 105 (71.2%) | ||
Obese | ||||
BMI > 30 (N = 111) | 39 (35.14%) | 72 (64.9%) | 1.748 (1.0712 to 2.854) | 0.0254 |
< 30 (N = 241) | 57 (23.7%) | 184 (76.3%) | ||
Arabs | ||||
Arabs (N = 120) | 45 (37.5%) | 75 (62.5%) | 2.1294 (1.314 to 3.451) | 0.0022 |
Non-Arabs (N = 232) | 51 (22%) | 181 (78%) | ||
Smoking | ||||
Smokers (N = 130) | 30 (23%) | 100 (77%) | 1.41 (0.85 to 2.29) | 0.2149 |
Non-smokers (N = 222) | 66 (29.7%) | 156 (70.3%) | ||
Combination therapy | ||||
Ezetimibe (N = 125) | 33 (26.4%) | 92 (73.6%) | 0.9337 (0.5682 to 1.524) | 0.8040 |
No Ezetimibe (N = 227) | 63 (27.75%) | 164 (72.25%) | ||
Atorvastatin dose | ||||
Moderate intensity (N = 180) | 41 (22.77%) | 139 (77.22%) | 1.593 (0.9928 to 2.5558) | 0.0536 |
High intensity (N = 172) | 55 (32%) | 117 (68%) | ||
Duration of therapy | ||||
Less than one year (N = 244) | 61 (25%) | 183 (75%) | 1.438 (0.87 to 2.378) | 0.1512 |
More than one year (N = 108) | 35(32.4%) | 73 (67.6%) | ||
SLCO1B1 rs4149056 | ||||
C allele Carriers (N = 69) | 28 (40.6%) | 41 (59.4%) | 2.202 (1.287 to 3.811) | 0.0063 |
Non-carriers (N = 283) | 68 (24.03%) | 215 (76.3%) | ||
SLCO1B1 rs2306283 | ||||
G allele Carriers (N = 252) | 71 (28.2%) | 181 (71.8%) | 1.177 (0.70 to 1.959) | 0.5970 |
Non-carriers (N = 100) | 25 (24.03%) | 75 (75.97%) | ||